Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing

Global Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market to Reach US$2.2 Billion by 2030

The global market for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. CT / NG Testing Consumables, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the CT / NG Testing Instruments / Analyzers segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.3 Million While China is Forecast to Grow at 9.3% CAGR

The Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing market in the U.S. is estimated at US$422.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$443.5 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market – Key Trends & Growth Drivers Summarized

Why Is CT/NG Testing Becoming a Critical Public Health Priority?

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are among the most prevalent sexually transmitted infections (STIs) worldwide, with millions of new cases reported annually. These bacterial infections often present asymptomatically, particularly in women, making routine screening essential for early detection and prevention of long-term complications such as pelvic inflammatory disease (PID), infertility, and ectopic pregnancy. In men, untreated infections can lead to epididymitis and increased susceptibility to HIV. The global burden of CT/NG infections has prompted governments, healthcare organizations, and public health agencies to strengthen STI screening programs, particularly among high-risk populations such as sexually active young adults, pregnant women, and individuals with multiple sexual partners.

The increasing emphasis on sexual health awareness and preventive healthcare has driven demand for accurate and accessible CT/NG testing solutions. Traditional culture-based diagnostic methods have largely been replaced by more advanced molecular techniques, including nucleic acid amplification tests (NAATs), which offer superior sensitivity and specificity. Additionally, growing concerns about antibiotic-resistant Neisseria gonorrhoeae strains have further highlighted the importance of early and reliable detection. However, challenges such as limited access to STI testing in low-resource settings, social stigma associated with STI diagnosis, and lack of awareness in certain regions continue to hinder market growth. Addressing these barriers through increased funding, policy support, and innovative testing solutions is crucial for controlling the spread of CT/NG infections.

What Are the Latest Technological Advancements in CT/NG Testing?

The CT/NG testing landscape has evolved significantly with advancements in diagnostic technologies that enhance accuracy, reduce turnaround times, and improve accessibility. One of the most significant innovations is the widespread adoption of NAATs, which detect and amplify bacterial DNA or RNA, providing highly sensitive and specific results in a short time. NAAT-based assays, such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), are now the gold standard for CT/NG testing due to their ability to detect low bacterial loads in urine, vaginal, cervical, and urethral samples. Furthermore, multiplex assays have been developed to simultaneously detect multiple sexually transmitted pathogens, improving diagnostic efficiency and enabling more comprehensive STI screening.

Point-of-care (POC) testing is another major breakthrough, offering rapid and decentralized testing options outside traditional laboratory settings. Portable molecular platforms, such as GeneXpert (Cepheid) and Abbott ID NOW, have made it possible to diagnose CT/NG infections in under an hour, facilitating same-day treatment and reducing transmission rates. Additionally, advancements in self-collection kits and at-home STI testing services have increased accessibility, allowing individuals to collect samples privately and send them to laboratories for analysis. The integration of artificial intelligence (AI) and digital health solutions into STI diagnostics is also emerging, with AI-powered diagnostic tools assisting in data interpretation, epidemiological tracking, and personalized patient management. As technological innovation continues, the CT/NG testing market is expected to expand, offering more efficient, user-friendly, and widely accessible testing options.

How Are Regulatory Policies and Market Trends Shaping the CT/NG Testing Industry?

The CT/NG testing industry is heavily influenced by regulatory policies, public health initiatives, and evolving market trends. Stringent guidelines from organizations such as the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the European Centre for Disease Prevention and Control (ECDC) emphasize the need for routine STI screening, particularly among high-risk groups. Governments worldwide are increasing investments in national STI control programs, expanding access to testing in community health centers, pharmacies, and primary care clinics. In addition, insurance coverage and reimbursement policies are improving, making CT/NG testing more affordable for patients in developed healthcare markets. However, disparities in healthcare infrastructure and diagnostic availability in low-income regions remain a significant challenge, limiting widespread STI screening.

Market trends indicate a growing preference for at-home and direct-to-consumer (DTC) STI testing, driven by the convenience, privacy, and accessibility these services provide. Companies such as Everlywell, LetsGetChecked, and myLAB Box have introduced self-testing kits that allow users to collect samples discreetly and receive lab-verified results online. Additionally, the integration of telemedicine with STI diagnostics is enabling remote consultations and prescription services, facilitating timely treatment and reducing the burden on healthcare facilities. The rise of digital health platforms is also playing a crucial role in streamlining CT/NG testing workflows, enabling electronic medical records (EMRs) integration, automated result notifications, and data-driven STI surveillance. As public awareness of STIs continues to rise, the demand for rapid, user-friendly, and cost-effective CT/NG testing solutions is expected to grow, influencing the future of STI diagnostics.

What Is Driving the Growth of the CT/NG Testing Market?

The growth in the CT/NG testing market is driven by several factors, including advancements in molecular diagnostics, increasing STI prevalence, and the expansion of decentralized and digital healthcare solutions. The rising incidence of CT/NG infections, particularly among young adults, has led to greater demand for routine screening and early detection. The continuous development of innovative molecular assays, including real-time PCR and automated high-throughput systems, has improved diagnostic accuracy and efficiency, making STI testing more widely available. Additionally, the adoption of self-collection and at-home testing kits has expanded access to screening services, addressing barriers related to stigma and healthcare accessibility.

End-use expansion is another major growth driver, with testing services being increasingly integrated into primary care settings, sexual health clinics, and online health platforms. The expansion of mobile health (mHealth) applications and telehealth services is further supporting the demand for digital STI diagnostics, enabling remote consultation, test ordering, and treatment access. Additionally, research into novel biomarkers and antimicrobial resistance (AMR) testing for Neisseria gonorrhoeae is paving the way for more comprehensive diagnostic solutions that not only detect infections but also guide targeted therapy. The increasing collaboration between diagnostic companies, public health agencies, and research institutions is accelerating product innovation and market penetration. As awareness campaigns and government-led STI prevention programs continue to expand, the CT/NG testing market is expected to experience sustained growth, offering more accessible, efficient, and patient-centric diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (CT/NG Testing Consumables, CT/NG Testing Instruments/Analyzers); Test Type (Laboratory Testing, Point-of-Care Testing); Technology (Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology, Other Technologies); End-Use (Hospitals and Clinics End-Use, Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux
• Bio-Rad Laboratories
• Cepheid
• DiaSorin
• GenMark Diagnostics
• Grifols
• Hologic, Inc.
• LabCorp
• Luminex Corporation
• Meridian Bioscience
• OraSure Technologies
• PerkinElmer
• Qiagen
• Quest Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.